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Abstract
Background: Using the streptozotocin-induced diabetic rat model, we have recently showed that
the expression and function of β1-adrenoreceptor were decreased in the diabetic rat heart.
However, the effect of diabetes on expression of β-adrenoreceptors in human cardiac tissue
remains undefined. Therefore, the focus of the present study was to investigate the effect of
diabetes on mRNA encoding β1- and β2-ARs in human atrial tissues.
Methods: Right atrial appendages from five diabetic (mean age 65 ± 4.5; 4 female, 1 male) and five
nondiabetic patients (mean age 56.2 ± 2.8; 4 male, 1 female) undergoing coronary artery bypass
grafting were collected and assayed using reverse transcriptase-polymerase chain reaction (RT-
PCR) for their mRNA content. No patient from these two groups suffered from acute myocardial
infarction and/or failure. All diabetic patients received insulin for at least two years and had been
diagnosed as diabetics for at least five years.
Results: When compared with levels in nondiabetics, steady state levels of mRNA encoding β1-
adrenoreceptor decreased by 69.2 ± 7.6 % in diabetic patients while β2-adrenoreceptor mRNA
decreased by 32.2 ± 5.5 % (p < 0.001).
Conclusions: Our findings show a decreased expression of β1- and β2-adrenoreceptors in human
diabetic atrial appendage.
Background
During the last two decades, significant efforts have been
made by several laboratories for a better understanding of
the molecular basis underlying cardiovascular complica-
tions in diabetics. As it is well known, these complications
are responsible for the increased incidence of morbidity
and mortality in this patient group and are brought about
by metabolic and biochemical shifts as well as by
ultrastructural alterations [1,2]. A substantial body of lit-
erature indicated that β-adrenoreceptors (AR)s are
involved in altered cardiac contraction and/or velocity in
different types and stages of heart disease. At early stages,
the heart compensate by increasing its neurohumoral and
neuroendocrine system activity. However, at later stages,
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excessive amounts of catecholamine stimulation could
have harmful effects on the already failing myocardium
[3]. Changes in expression and function of β-ARs depend
on the type and stage of heart failure and also depend on
the region of the heart [4].
Some of the hallmarks of diabetes induced cardiomyopa-
thy are bradycardia, nonhomogeneity of atrial conduction
and prolongation of sinus node recovery times [5]. Our
laboratory previously demonstrated that diabetes has
altered the responsiveness, function and expression of the
β-ARs in the STZ-diabetic rat heart [6–8]. In addition to
STZ-diabetic rat model, we also studied the inotropic
responses to β-AR stimulation using atrial appendages
from diabetic and nondiabetic humans. In those studies
we demonstrated that the full agonist potency order was
isoprenaline = fenoterol > noradrenaline [8]. However, no
data is currently available on the levels of β-ARs in human
diabetic atria. Thus, the aim of the present study was to
compare the relative levels of β-AR subtypes in diabetic
and nondiabetic human atrial appendages.
Methods
Patient Characteristics
Protocol for collection, storage and analysis of human tis-
sues was reviewed and approved by the Bas ¸kent University
School of Medicine Ethics Committee. Age and sex disper-
sion as well as medical history of subjects were prospec-
tively obtained from 51 diabetic and nondiabetic patients
from undergoing coronary bypass operation in cardiovas-
cular department for two month period. However, only
10 atria selected and collected (5 of each group) to ana-
lyze mRNA expression. For the purpose of this study, sam-
ples for analysis based on the following criteria; they
should (i) be angiographically proven coronary artery dis-
ease. The point that all patients presented with coronary
artery disease is important because it allows for the inter-
pretations that differences between nondiabetic and dia-
betic tissues most likely reflect the presence of diabetes,
not just due to the consequences of ischemia (ii) have not
suffered from prior acute myocardial infarction and/or
heart failure (iii) the nondiabetic group has no history of
cardiac diseases (they were sudden angina pectoris and
then needed by-pass operation), and (iv) all diabetic
patients have been diagnosed for at least five years and
receiving insulin therapy (24 ± 5 U/day) for at least two
years. Using these criteria, five diabetic (insulin-treated)
samples (age; 65 ± 4.5, sex; 4F/1M, n = 5) and five nondi-
abetic samples (age, 56.2 ± 2.8; 4M, 1F) were chosen for
mRNA analysis. The diabetic group had been treated with
insulin (n = 5), calcium antagonists (n = 2), nitrovasodi-
lators (n = 2) and aspirin (n = 5), on the other hand
nondiabetic patients had received calcium antagonists (n
= 2), ACE inhibitors (n = 2) and aspirin (n = 2). None of
the patients received β-AR blocking agents for their medi-
cation before the operation. All diabetic patients had nor-
mal glucose concentration before the operation.
Dolantin, promethazine and atropine were given as pre-
medication and operation was carried out under balanced
anaesthesia with fentanyl and isoflurane. Heparin, pred-
nisolone, dopamine, nitroglycerin and anti-arrhythmic
were also given to some patients.
Isolation and quantitation of total RNA
Atrial appendages (≈ 100 mg tissues) removed, placed in
liquid N2  and then stored at -80°C. Total RNA were
extracted using the procedure provided with Quick Prep®
total RNA extraction kit (Amersham Pharmacia Biotech,
Piscataway, New Jersey) as described before [6,9]. At the
end of the isolation, RNA samples were dissolved in
diethylpyrocarbonate (DEPC)-treated water (pH 7.5) and
the optical density (OD) values of each sample were deter-
mined spectrophotometrically using UV-visible spectro-
photometer (UV-1601, Shimadzu, Japan) at wavelength
260 nm (λ260) and 280 nm (λ280). The amount of RNA in
each sample was then determined using the formula,
[RNA] = ODλ260 X dilution factor X 40 µg/ml. OD values
of RNA samples were also determined at λ280 and the
ODλ260 / ODλ280 ratio were used as cursory estimations of
RNA quality (6). RNA samples were electrophoresed using
denaturing (formamide/ formaldehyde) agarose gels to
qualitatively assess for any degradation that may have
occurred during the isolation.
Preparation of first strand cDNA via reverse transcriptase 
reactions
RNA samples with distinct 18S and 28S ribosomal RNA
bands on denaturing agarose gels were then used as tem-
plates for synthesis of first strand cDNAs as described pre-
viously (6, 9). Briefly, 1 µl of oligo dT12–18  (Life
Technologies-Gibco BRL, Gaithersburg, MD, USA) was
added to equivalent amounts of total RNA from control
and diabetic human atrial appendages. The mixtures were
then placed into a thermocycler (Hybaid, PCR Express,
UK) and held at 70°C for 10 min. At the end of this time,
the samples were transferred into ice bath for 5 min to
permit selective binding of the oligo dT12–18 to the poly-A
tail of the mRNA. Thereafter, 1 µl of 10 mM deoxynucle-
otide triphosphate (dNTP), 2 µl of 0.1 M dithiothreitol
(DTT), 4 µl of 5 X 1st strand buffer, 1 µl Superscript II and
1 µl RNasin were added followed by water for a final vol-
ume of 20 µl. The tubes were again placed into the ther-
mocycler and heated for 45 min at 42°C for reverse
transcription followed by 5 min at 94°C for denaturation.
First strand cDNA samples were then cooled to 4°C and
stored at -80°C until use.
Amplification of cDNA encoding β-AR subtypes
PCR reactions using gene specific primers were used to
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each sample. For this, 5 µl of 10 X Tfl buffer, 25 mM
MgCl2 (Table 1), 1 µl of 100 mM dNTP, 0.2 µl of Taq DNA
polymerase (5 U/µl) (Promega, Madison, WI, USA), 3 µl
of either control or diabetic human heart cDNA and 2 µl
(from 25 µM stocks) of respective sense and anti-sense
primers were added to PCR tubes (Table 1). DEPC water
was then added to each tube for a final volume of 50 µl.
The samples were then mixed, placed in the thermocycler
and denatured for 3 minutes at 94°C. Amplified were car-
ried out using the program: 1 min denaturation (94°C)
followed by 1 min annealing and 2 min extension
(72°C), repeated for a total of 35. β-actin was amplified in
each set of PCR reactions and this gene served as internal
references during quantitation to correct for operator and/
or experimental variations. At the end of the reactions, 25
µl of each PCR product was mixed with 5 µl of 2 X Blue/
Orange loading dye and the samples were loaded onto a
2 % agarose gel containing ethidium bromide and electro-
phoresed for 2 hr at 100 V (Sci-plas, England). The result-
ing gels were then visualized using an ultraviolet trans-
illuminator (Viber Loumat TFX 20 M UV) and photo-
graphed using UV gel camera (Polaroid GH 10, UK).
Images of the gels were scanned into Adobe Photoshop®
3.0 (Adobe Systems Incorporated, Mountain View, CA,
USA) and then imported into Scion Imaging Software,
Version 1.62 (Frederick, MD, USA, http://scioncorp.com).
Areas under the curves were measured and used as mRNA
concentrations.
Data analysis and statistics
Differences between values of all groups were evaluated
by student t test. The experimental data are mean ± stand-
ard error of mean (S.E.M) of n experiments. Results were
considered significantly different at P < 0.01.
Results
Age and sex dispersion of subjects
Right atrial appendages were obtained from a total of 51
patients undergoing coronary by-pass operation in
Department of Cardiovascular Surgery at Baskent Univer-
sity, Ankara Turkey for two month period. Analysis of data
prospectively evaluated from 51 patients revealed that 35
patients (68.63%) were nondiabetic and 16 were diabetic
(31.37%) (Figure 1B). Of the 35 nondiabetic patients, 27
patients were males (53.0% of total, mean age of 59.4 ±
9.8 years) and 8 patients were females (15.7% of total;
mean age of 62.4 ± 7.5 years) (see Figure 1A,1B). These
data indicate that more than three times as much nondia-
betic males underwent coronary by-pass surgery at
Baskent University during this period than non-diabetic
females (Figure 1B). In the diabetic group, 9 patients were
males (17.6% of total; mean age of 62.2 ± 7.9 years) and
7 were females (13.7% of total; mean age of 66.1 ± 9.0
years), Figure 1A,1B. Therefore, during the period approx-
imately similar amounts of males and females diabetic
patients underwent coronary by-pass surgery at Baskent
University (Figure 1B).
For this study only ten of the 51 samples satisfied the
selection criteria (nondiabetic group; mean age, 56.2 ± 2.8
and sex 4M/1F, n = 5, diabetic group; mean age, 65 ± 4.5
and sex, 4F/1M, n = 5) and collected for mRNA expression
experiment.
Quantitation of total RNA isolated from human hearts
Optical density (OD) values at λ260 and ratios of ODλ260/
ODλ280 were used to quantitate as well as to estimate the
quality of total RNA isolated from the diabetic and nondi-
abetic human atria. All samples used for analysis were of
similar quality (ODλ260/ODλ280 ratios ~ 1.7) and showed
distinct 18 and 28S bands on denaturing agarose gels.
Table 1: Primers used in PCR reactions.





β1-ARs (sense) 236CGAGCCGCTGTCTCAGCAGTGGACA260 201 54 1,2
β1-ARs(antisense) 436GGTGGCCCCGAACGGCACCACCAGCA412
β2-ARs (sense) 2135ACTGCTATGCCAATGAGACC2154 463 59 1,2
β2-ARs(antisense) 2597TGGAAGGCAATCCTGAAATC2578
β-actin (sense) 1079AAGTACTCCGTGTGGATCGG1098 286 54–59 1,2–1,3
β-actin(antisense) 1364CACCTTCACCGTTCCAGTTT1345
β-actin (sense) 854CTCTTCCAGCCTTCCTTCCT873 513 54–59 1,2–1,3
β-actin(antisense) 1366GTCACCTTCACCGTTCCAGT1347
Primers were designed based on published sequences in the National Center for Biotechnology Information GenBank database http://
www3.ncbi.nlm.nih.gov/entrez/: β1-ARs accession number NM_000684) [24]; β2-ARs (accession number XM_004030); β-actin (accession number 
NM_001101). Subscript numbers refer to positions of bases within the published cDNA sequences.Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/6
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Patients undergoing coronary arterial by-pass grafting during a two month period at Baskent University, Ankara, Turkey Figure 1
Patients undergoing coronary arterial by-pass grafting during a two month period at Baskent University, Ankara, Turkey. (A) 
mean age of patients (B) Percentage distribution of patients according to gender and diabetic state.Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/6
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Quantitation of β-AR transcripts
After converting mRNAs into more stable cDNAs,
polymerase chain reactions were used to determine the
amounts of β-AR transcripts in hearts of control and dia-
betic human atria. As shown in Figure 2, diabetes signifi-
cantly decreases (P < 0.001) mRNA levels of β1-ARs to
69.2 ± 7.6 (Figure 1A) and β2-ARs to 32.2 ± 5.5 % (Figure
2B) of control in diabetic human atria. Also β1/β2 mRNA
ratio was 67% in nondiabetic and this ratio was lowered
to 43% in diabetic human atrial appendages (Figure 3).
All data points were normalized to β-actin as its mRNA
levels did not change significantly in this experimental
paradigm (Figure 2C).
Discussion
We have previously demonstrated that β1-ARs mediated
chronotropic responses decreased by 29%, but β2-ARs
mediated responses preserved in 14-week diabetic rat atria
[8]. In the same study the inotropic responses to β-AR ago-
nists were also studied on diabetic and nondiabetic
human atrial tissues. The full agonist potency order was
isoprenaline > or = fenoterol > noradrenaline. We have
also previously demonstrated that β1-ARs mRNA
decreased to 65.1 % but β2-ARs mRNA expression
increased to 72.5 % in 14 week STZ-diabetic rat heart [6].
In this study we used human atrial appendages obtained
from highly selected group of patients. Unfortunately, this
lead to a very small final population. Unlike the STZ-
induced diabetic rat model, it is very difficult to find out
large sample size of patients. Nevertheless, our present
result (decreased to 69.2 ± 7.6%) in human atrial append-
age related with β1-ARs mRNA expression is very similar
if compared with our previous results in the 14-week STZ
diabetic rat heart.
As a matter of fact, β2-ARs expression is still indefinite,
contrarily to the β1-AR subtype in different model of heart
failure. Bristow et al. demonstrated that β1- but not β2-ARs
are downregulated by 50% in the human ventricles, not
specifically in diabetic heart but during CHF [10].
Decreased expression of β1-ARs and stimulatory protein
Gs and increased expression of inhibitory protein Gi have
extensively been investigated in different types of human
heart failure by many investigators [10–15]. Like the other
types of heart failure, high levels of circulating catecho-
lamine levels lead to decreased expression of cardiac β-
ARs and to diminished β-ARs mediated inotropic and
chronotropic responses in the diabetic heart [16,17]. The
hazardous effects of elevated catecholamine levels are
mediated primarily by β1-ARs, contrary to β2-ARs stimula-
tion, which may be adaptive in some cases [15]. Neverthe-
less, in contrast to other types of heart failure, the diabetes
mellitus is a complex metabolic disorder and the eleva-
tion of circulating blood glucose level possibly alters the
structures of many proteins in the heart. These structural
and ultrastructural alterations could lead to transcrip-
tional or posttranslational modifications of these pro-
teins. However, if insulin therapy is applied, the cardiac
disturbances could be restored partially or completely in
the early stage of diabetic heart even if catecholamine lev-
els are still considerably high [6,9]. In the early stage, the
cardiac disturbances can return to almost normal levels by
insulin therapy, unfortunately, in more chronic stages this
is mostly irreversible. For this reason, probably the blood
glucose variations shift the present disturbances to the
irreversible side and/or trigger the initiation of new
pathologies in the diabetic heart.
As it is well known, β1- and β2-ARs each couple to Gs.
However, a growing body of recent evidence suggests that
β2-ARs, but not β1-ARs also couple to the inhibitory pro-
tein Gi [14,15]. Brodde et al. indicated that β2-ARs are
more effectively coupled to adenylate cyclase than are β1-
ARs in the human right atrium [18]. They also suggested
that isoprenaline and adrenaline cause almost same
increases in force of contraction via β1- and β2-ARs stimu-
lation because of the more effective coupling of β2 ARs to
adenyly cyclase in vitro on isolated human right atrium in
spite of the predominance of β1-ARs density [18]. Simi-
larly, we have previously demonstrated that β2-selective
agonist fenoterol was more potent than β1-selective ago-
nist noradrenaline on the human right atrium obtained
from coronary artery by-pass grafting diabetic and nondi-
abetic patients [8].
At the same time, we used PCR reactions that simultane-
ously amplify cDNAs encoding for β3-AR in different
MgCl2 concentrations as well as annealing temperatures.
Different set of gene specific primers were used for β3-AR
transcripts: sense 839CCTTCCTCTTCTCGTGATGC858 and
anti-sense-1492TCTGAACAGAGGCCAGAGGT1473, sense
1659AGTGGTAGTGTCCAGGTGCC1678  and anti-sense
2156AAGCCAGCGCAGAGTAGAAG2137, (Primers were
designed based on published sequences in the National
Center for Biotechnology Information GenBank database;
http://www3.ncbi.nlm.nih.gov/entrez/, accession
number NM_000025) and sense
AGGTTATCCTGGATCACATG and anti-sense CTGGCT-
CATGATGGGCGC (Last primers based on the previous
report; Gauthier, 1996) [22]. Consequently we could not
detect the presence of β3-AR mRNA expression in human
atrial appendage from both patient groups. It may depend
on very small amount of β3-AR mRNA expression in
human atrial appendage.
In our present study we also found that β1/β2 mRNA ratio
was 67% in nondiabetic however, 43% in diabetic human
atrial appendages (Figure 3). Brodde et al. also demon-
strated that atrial and ventricular β1- and β2-ARs densityCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/6
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Reverse transcription-polymerase chain reaction (RT-PCR) products obtained from diabetic (5) and nondiabetic (5) human  atrial appendages Figure 2
Reverse transcription-polymerase chain reaction (RT-PCR) products obtained from diabetic (5) and nondiabetic (5) human 
atrial appendages. Total RNA was reverse-transcribed using oligo dT12–18 and the first strand cDNA was subjected to amplifica-
tion by PCR. The samples were loaded onto 2% agarose gel and electrophoresed for 2 hr at 100 V. A. Example and quantita-
tion of signals for β1-AR obtained using RT-PCR reactions. B. Example and quantitation of signals for β2-AR obtained using RT-
PCR reactions. C. Example and quantitation of signals for β-actin obtained using RT-PCR reactions. Values shown are mean ± 
SEM obtained from five experiments. *P < vs. control group.Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/6
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was different in human myocardium [the β1/β2 ratio is
about 60/70:40/30 % in the atria ; 70/80:30/20 % in the
ventricles] [20]. Furthermore, Rodefeld et al.
demonstrated that in human sinoatrial nodes β1-ARs den-
sities were 3 times and β2-ARs densities were 2.5 times
higher than right atria. However β1-AR subtypes predom-
inate in sinoatrial node [21]. We can also speculate that
β1- and β2-ARs mRNA expression and β1/β2 ratio could be
attenuated in sinoatrial node in diabetic patients and it
could be one of the reason to decreased chronotropism
seen in diabetic patients. Further studies are necessary to
reveal the disturbances of sinoatrial β-ARs subtypes in dia-
betic atria.
Limitations
Study results are obtained from very small final popula-
tion. This mainly depends on highly selected group of
patient samples. Due to the same reason, age differences
between diabetic and non diabetic subgroups look quite
different and this may influence the results. Age-associ-
ated diminution in myocardial β-ARs has been widely
demonstrated. However, Brodde et al. demonstrated that
β-AR function with increasing age is not due to alterations
in receptor density but involves an impairment of the
activity of the catalytic unit of the adenylyl cyclase in
human right atrium [23].
Conclusions
The principal finding of the present study is that in dia-
betic human atria, β1-ARs mRNA expression is extensively
decreased, while β2-ARs mRNA expression is moderately
decreased.
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